OTCPK:AQSZF (Canada)  
Aequus Pharmaceuticals Inc logo

Aequus Pharmaceuticals Inc

$ 0.03 0 (0%) 09:40 AM EST
P/E:
At Loss
P/B:
9.29
Market Cap:
$ 6.75M
Enterprise V:
$ 6.72M
Volume:
-
Avg Vol (2M):
11.96K
Also Trade In:
Volume:
-
Market Cap $:
6.75M
PE Ratio:
At Loss
Avg Vol (2-Month):
11.96K
Enterprise Value $:
6.72M
PB Ratio:
9.29
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download Tutorials

Business Description

Aequus Pharmaceuticals Inc
NAICS : 325412 SIC : 3741
200 Granville Street, Suite 2820, Vancouver, BC, CAN, V6C 1S4
Description
Aequus Pharmaceuticals Inc is a Canada based specialty pharmaceutical company. The firm's operating segments are the Commercial platform and Development pipeline. It generates a majority of its revenue from the Commercial platform segment. Aequus is developing a pipeline of products in neurology and psychiatry. The company's launched and pipeline products are Tacrolimus IR, Vistitan, AQS1304, AQS1303, and others.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt 1.01
Equity-to-Asset 0.25
Debt-to-Equity 2.47
Debt-to-EBITDA -1.44
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -9.63
Distress
Grey
Safe
Beneish M-Score 2.86
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 7.99
9-Day RSI 29.03
14-Day RSI 38.53
6-1 Month Momentum % -86.03
12-1 Month Momentum % -90.06

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 1.09
Quick Ratio 1.04
Cash Ratio 0.87
Days Inventory 1341.91
Days Sales Outstanding 86.7
Days Payable 2318.82

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -18.1

Profitability Rank

Name Current Vs Industry Vs History
Gross Margin % 98.69
Operating Margin % -66.38
Net Margin % -83.37
ROE % -114.07
ROA % -48.24
ROIC % -81.84
ROC (Joel Greenblatt) % -216.72
ROCE % -61.9

GF Value Rank

Name Current Vs Industry Vs History
PS Ratio 3.61
PB Ratio 9.29
EV-to-EBIT -5.16
EV-to-EBITDA -5.59
EV-to-Revenue 3.4
EV-to-FCF -7
Earnings Yield (Greenblatt) % -19.38

Financials

AQSZF's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with OTCPK:AQSZF

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 2.005
EPS (TTM) ($) -0.013
Beta 0.59
Volatility % 96.47
14-Day RSI 38.53
14-Day ATR ($) 0.008158
20-Day SMA ($) 0.04124
12-1 Month Momentum % -90.06
52-Week Range ($) 0.0013 - 0.12232
Shares Outstanding (Mil) 132.63

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Aequus Pharmaceuticals Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More